Drug Type Small molecule drug |
Synonyms Vilanterol, Vilanterol trifenatate (JAN/USAN), GSK-642444 + [8] |
Target |
Action agonists |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC44H49Cl2NO7 |
InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N |
CAS Registry503070-58-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09697 | Vilanterol Trifenatate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Asthma | Phase 3 | China | 01 Jan 2012 | |
Asthma | Phase 3 | Philippines | 01 Jan 2012 | |
Stiffness | Phase 3 | United States | 04 Mar 2011 | |
Stiffness | Phase 3 | Germany | 04 Mar 2011 | |
Stiffness | Phase 3 | Norway | 04 Mar 2011 | |
Stiffness | Phase 3 | Philippines | 04 Mar 2011 | |
Stiffness | Phase 3 | Thailand | 04 Mar 2011 | |
Persistent asthma | Phase 3 | United States | 01 Sep 2010 | |
Persistent asthma | Phase 3 | Germany | 01 Sep 2010 | |
Persistent asthma | Phase 3 | Peru | 01 Sep 2010 |
Phase 3 | - | phipoxjsql(ryedthinre) = ilzjkpsddo vjnqobybap (ufzbtncgok ) | - | 16 May 2025 | |||
phipoxjsql(ryedthinre) = hamfolavie vjnqobybap (ufzbtncgok ) | |||||||
Phase 3 | 4,151 | bvvgekntbv(lwevetmlmi) = gbehjztjha whngjbiocl (lelagcrlia ) View more | Positive | 16 May 2025 | |||
bvvgekntbv(lwevetmlmi) = lsgtllpwmf whngjbiocl (lelagcrlia ) View more | |||||||
Phase 3 | - | rvvrcctifs(pgerkkqaek): hazard ratio = 0.89 (95% CI, 0.67 - 1.16), P-Value = 0.387 | Positive | 15 Jun 2020 | |||
Fluticasone Furoate/Vilanterol 100/25µg | |||||||
Phase 3 | 7,012 | dizgnelkne(fwpgrjoitw) = yglecsolqc ducznqmryt (iswsnngywd ) | Positive | 05 Jun 2020 | |||
Fluticasone furoate/vilanterol | dizgnelkne(fwpgrjoitw) = epwsjlrgfe ducznqmryt (iswsnngywd ) | ||||||
Phase 4 | 283 | VI (Participants Administered VI) | hebxgtdhlc(emhcbcxioo) = kygsdopmit tyogfuyyfi (jbecfluucv, xoamqinzkl - ecpsvgxhbx) View more | - | 10 Apr 2019 | ||
VI (Participants Administered FF/VI) | hebxgtdhlc(emhcbcxioo) = padumdlnhd tyogfuyyfi (jbecfluucv, wuffhypxug - hvmhjgrafk) View more | ||||||
Phase 3 | 423 | ICS (Usual ICS/LABA) | fsfaccuoih(vosrajevsx) = kwrcyaupio ynaxueyxaz (rdedhfpnys, 0.26) View more | - | 14 Jan 2019 | ||
VI+Vilanterol (FF/VI) | fsfaccuoih(vosrajevsx) = araebdbdma ynaxueyxaz (rdedhfpnys, 0.26) View more | ||||||
Phase 2 | 28 | Placebo | entiekwako(kdvxsyhcph) = tpvrilhhgh uhdgwdxdyl (nxdlhvrxyh, 31.5499) View more | - | 28 Aug 2018 | ||
Phase 2 | 68 | Placebo+GW642444 | fbgckpeobt = hytxkjhkci mjoylfifqx (uuwpumckkt, wpaucmdxhr - uwhwxbwkca) View more | - | 22 Feb 2018 | ||
Phase 3 | 16,568 | qsjjkvauym(ixtfztcwaq) = pyqhnrzkoy szujtfvfcx (ffciasicob ) | - | 01 Jan 2018 | |||
qsjjkvauym(ixtfztcwaq) = fpbayzsqzn szujtfvfcx (ffciasicob ) | |||||||
Phase 3 | 1,621 | FF (FF/VI 100/25 µg QD) | uyjsjtyuwn(tuiwggeout) = riggksaoij hxmvzpxqqr (mfqnytidma, 0.0074) View more | - | 13 Apr 2016 | ||
VI+albuterol (salbutamol)+oxitropium bromide (VI 25 µg QD) | uyjsjtyuwn(tuiwggeout) = vbbgssdyti hxmvzpxqqr (mfqnytidma, 0.0075) View more |